TORONTO (Reuters) - Valeant Pharmaceuticals International Inc VRX.TO VRX.N said on Monday it has agreed to acquire privately held PreCision Dermatology Inc for $475 million in cash to strengthen its skin products business.
The deal, which is set to close in the first half of 2014, is expected to immediately add to Valeant’s cash earnings per share after closing.
Valeant, Canada’s largest listed drugmaker, is striving to become one of the world’s top five pharmaceutical companies by market capitalization by the end of 2016, largely through acquisitions, the company said last month.
The company has expanded rapidly via a steady stream of deals, and the latest is consistent with comments by senior executives in October that the drugmaker was seeking small, cash-based acquisitions in the near term.
“While we note that PreCision is merely a small step toward Valeant’s more ambitious goals of adding $150 billion in market capitalization by 2016, we think the acquisition, much like Solta’s recent acquisition, makes strategic sense,” said Stifel Nicolaus analyst Annabel Samimy, in a note to clients.
In December, Valeant said that it had agreed to buy Solta Medical for about $236 million in cash to add products for procedures such as skin rejuvenation, skin tightening and body contouring to its portfolio.
Cumberland, Rhode Island-based PreCision, expects revenue of about $130 million in 2014. J.P. Morgan Securities LLC acted as PreCision’s financial advisor on this deal.
PreCision, which makes a range of medical products treating a number of topical diseases such as acne and atopic dermatitis, is entitled to an additional $25 million if it achieves a sales milestone, Valeant said.
PreCision - formed in 2010 as the result of the spin-out of Onset Therapeutics, a subsidiary of Collegium Pharmaceutical - was initially financed by private equity firms Essex Woodlands, Boston Millennia Partners, Frazier Healthcare and Westfield Capital Management.
“This deal is yet another example that there are plenty of small-mid sized acquisition opportunities available for Valeant” said BMO Capital Markets analyst Alex Arfaei in a research note.
Shares in Valeant, which have more than doubled in value in the last twelve months, fell less than 1 percent to $135.23 in early New York trading on Monday.
Reporting by Euan Rocha in Toronto and Ashutosh Pandey in Bangalore; Editing by Ted Kerr, Sofina Mirza-Reid and Nick Zieminski